Immunogenicity and safety of the BBIBP‐CorV vaccine in patients with autoimmune inflammatory rheumatic diseases undergoing immunosuppressive therapy in a monocentric cohort
Abstract Introduction Vaccination plays a fundamental role in mastering the COVID‐19 pandemic and protecting vulnerable groups. Persons with autoimmune inflammatory rheumatic diseases (AIIRD) requiring immunosuppressive therapies are prioritized for vaccination. However, data concerning immunogenici...
Main Authors: | Batool Zamani, Amin Moradi Hasan‐Abad, Ahmad Piroozmand, Mahsa Dehghani, Maryam Arfaatabar, Hossein Motedayyen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-05-01
|
Series: | Immunity, Inflammation and Disease |
Subjects: | |
Online Access: | https://doi.org/10.1002/iid3.858 |
Similar Items
-
Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco
by: Yaowen Zhang, et al.
Published: (2022-08-01) -
Persistence of immune responses to the Sinopharm/BBIBP‐CorV vaccine
by: Chandima Jeewandara, et al.
Published: (2022-06-01) -
Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
by: Kriangkrai Tawinprai, et al.
Published: (2022-05-01) -
Neutralizing Antibody Response to BBIBP-CorV in Comparison with COVID-19 Recovered, Unvaccinated Individuals in a Sample of the Pakistani Population
by: Javeria Aijaz, et al.
Published: (2022-04-01) -
Vaccination with the Inactivated Vaccine (Sinopharm BBIBP-CorV) Ensures Protection against SARS-CoV-2 Related Disease
by: Chao Wang, et al.
Published: (2022-06-01)